Day Traders, Penny Stocks, Stock Options, Futures and Forex

Ingen Cuts Manufacturing Costs and Increases Its Margins
Company Increases Its Profit Margins by 50%

Press Release
Source: Ingen Technologies, Inc.
On 4:15 pm EDT, Wednesday October 14, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Global Medical Device manufacturer focused in the $4 billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California. The company CEO, and some of the management staff received a proposal on Wednesday last week to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. On Friday last week, they had a meeting in Pomona with the new manufacturer to discuss the new manufacturing and distribution of Oxyview and the new Oxyview Nasal Cannula.



"Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Ingen Technologies,Inc. - Home



About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

iv been on and off with them for a while now and they have been good to me but With them receving that proposal to reduce prodution and material cost by 50% along with sales going up to give them a foothold in the market im back on again

i also hung in there yesterday , it looks like it gonna pay off poss more good news at close today

Penny Stocks - Forum for Day Traders - Hot Penny Stock Picks and Forex Trading to GoogleReader!
Nadine

Today's Ingen CEO Live Interview With The Money Channel
CEO Talks About Increased Sales and Corporate Dedication to Growth

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EDT, Thursday October 22, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, will present the Sales and Marketing program for the new Oxyview Nasal Cannula on the live broadcast of The Money Channel's American Scene Radio scheduled later today at 11:34 AM eastern standard time.


Related Quotes
Symbol Price Change
IGNT.PK 0.0034 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
On October 31, 2009, Medco Forum will introduce the Oxyview Nasal Cannula at the 2009 Annual Meeting of the American College of Chest Physicians in San Diego-California. The American College of Chest Physicians (ACCP) is a multidisciplinary international medical society with more than 16,000 active members representing more than 100 countries.



On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.



On January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health in Dubai. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.



The company advertising in COPD Digest was released on September 14, 2009 to approximately 185,000 clinicians, patients and medical managers and will continue throughout 2010 with a full page editorial and a second full page color ad for every issue. COPD Digest is published with the support of, and contributions from, organizations representing the entire COPD community with a national subscriber base of more than 180,000.



The advertising for Today's Senior Magazine was released September 28, 2009 to approximately 180,000 subscribers. The next issue will feature an introductory price of the Oxyview Nasal Cannula. Today's Senior Magazine is a senior magazine that provides important information, plus local and national products and services for people fifty and over, with 150,000 California subscribers and 30,000 Texas subscribers.



The company has front cover full page editorials with Medco Forum for the fall. Medco Forum is a well-respected medical newsletter written and edited by a select editorial team composed of both physicians and professional medical journalists. Its purpose is to provide healthcare professionals with an exclusive preview of the latest innovations in their medical field prior to their annual conference.



The company reported gross sales of $106,483 in the quarter ended August 31, 2009. This represented an increase from sales of $987 in the quarter ended August 31, 2008. Sales were further sparked by the introduction of an "all-in-one" Oxyview Nasal Cannula unit that includes a cannula with the Oxyview unit. Additional capital also enabled Ingen to increase the advertising and marketing of the Oxyview products. The company anticipates sales of Oxyview to increase from the current quarter's sales as they expand sales channels.



The total cost of sales was $38,804 in the quarter ended August 31, 2009 and the gross profit was $67,679 (a gross margin of 63.6%).



The selling, general and administrative expenses were $598,442 in the quarter ended August 31, 2009. This was an increase of approximately 53.79% from the selling, general and administrative expenses of $276,933 reported in the quarter ended August 31, 2008. The increase in SG&A was due, in part, to additional advertising and marketing fees and increased amounts paid for outside services.



The largest components of the SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. Advertising expense increased from zero in the quarter ended August 31, 2008 to $67,679 in the quarter ended August 31, 2009. The company expects to continue advertising at current levels as the company promotes the new Oxyview Nasal Cannula.



The amounts paid for outside services increased to $163,922 in the quarter ended August 31, 2009 from $61,276 in the quarter ended August 31, 2008 (an increase of 168%). The company is utilizing more outside services for office growth and in the development of a sales and support staff for anticipated increases in sales.



The Company has recorded patents at a cost of $67,345. There are 3 issued patents (2 in the U.S. and 1 in China), and there are 7 pending patents combined in the U.S., Canada, Japan and Europe expected to be granted and issued in 2010. The patents have added value to the intellectual property and will strengthen the market share for the new Oxyview Nasal Cannula.



Medco Forum - About Us



American College of Chest Physicians



Welcome to the COPD Digest!



Senior Living : Retirement : Elderly Health : Today's Senior Magazine



MEDICA 2009 - Messe Düsseldorf North America



index



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

thankyou everyone for gaining knowledge from my newsletter. ive been out for to days but im getting back in ignt this morning. news came out the 20th and yesterday so being that this is a newsletter stock im betting that its going to run great today, ive flipped this stock a couple times and all in all its made me lots of money.

Ingen Brings Aboard Leading OEM Partner for Australia
Medical Industries Australia Pty LTD Signs OEM Contract

Press Release
Source: Ingen Technologies, Inc.
On 3:15 pm EDT, Friday October 23, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.


Related Quotes
Symbol Price Change
IGNT.PK 0.0038 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.



In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.



In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.



"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Medical Industries Australia > Home



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Ingen CEO Live Radio Interview Today With The Money Channel
Increased Sales, Margins and Profits Bring Bright Future for Shareholders

Press Release
Source: Ingen Technologies, Inc.
On 12:38 pm EDT, Tuesday October 27, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, discussed increased profits, margins and sales at 11:34am eastern daylight time today on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.0030 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"The company sales for first quarter had increased more than a 100 times compared to last year due to the acceptance of the product by the home oxygen patients and respiratory medical market. Margins of sales were slightly better than 63%. The future of this company for any investor, compared to other companies in the market place, is strong and steady," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



The company introduced a new revolutionary product into the medical market this past June-2009, called the Oxyview Nasal Cannula. Oxyview, the World's First Patient In-Line Oxygen Flow-Meter, and Oxyview Nasal Cannula, the World's First Cannula with a built-in oxygen flow meter is another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients who require home oxygen therapy or supplemental oxygen.



Welcome



Medco Forum - About Us



American College of Chest Physicians



The Digest - Log!c



Senior Living : Retirement : Elderly Health : Today's Senior Magazine



MEDICA 2009 - Messe Düsseldorf North America



index



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Ingen Engages New SEC Auditing Firm
Company Legal and Accounting Team Focuses on SEC Filings

Press Release
Source: Ingen Technologies, Inc.
On 3:54 pm EDT, Friday October 30, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has hired Anton & Chia, LLP as the new auditing firm after dismissing Child, Van Wagoner and Bradshaw on Wednesday of this week.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The Irvine-California based Anton & Chia's team of professionals consist of certified public accountants that are able to assist Ingen with the 10-KSB ending May 31, 2009 and future filings. This firm has over 40 years of experience working with small to middle market companies and understands Ingen's needs. Anton & Chia are licensed CPAs in the following states: California, Colorado, Florida and New York and have a professional staff that are fluent in speaking and writing Mandarin, Cantonese, Italian, and Spanish. As specialists in the realm of public company accounting and reporting, the professionals of Anton & Chia, LLP go to great lengths to ensure the accuracy and timeliness of required financial reporting, compliance and transaction-related issues for our public clients. With the immediate needs of Ingen, Anton & Chia will assist the company in preparing for and meeting obligations in the increasingly complex regulatory environment of public companies in order to comply with rules of the U.S. Securities and Exchange Commission (SEC) and obligations promulgated by the Sarbanes-Oxley Act of 2002.



"We found a firm that can meet our filing schedule. Our legal and accounting team is working very close with the SEC and the new auditors to complete and file the 10-KSB ending May 31, 2009 and subsequent 10-Q's to bring current our filing obligations," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Anton & Chia, LLP



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Pinnacle Digest: Looking For Shareholder Opinions On Ingen Technologies' Latest News

Nov 02, 2009 (M2 PRESSWIRE via COMTEX) -- www.******************* is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that the company has hired Anton & Chia, LLP as the new auditing firm after dismissing Child, Van Wagoner and Bradshaw on Wednesday of this week, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Join The Ingen Investor Discussion Here: http://www.*******************/company/ignt

Join ******************* to

Find out if Ingen makes it as a Pinnacle Featured Company,

Chat with other shareholders invested in Ingen,

Explain to our investor community what differentiates this company,

Connect with investors and professionals in the equity markets,

Meet the thousands of investors who have already become members of the Pinnacle community.

******************* is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

******************* has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated ******************* in any form to disseminate this release.

This source of information is from an unbiased perspective. If you wish to become a member of www.******************* you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by ******************* (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by ******************* to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ******************* is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ******************* may receive compensation in cash or shares from independent third parties or from the companies mentioned.

******************* will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ******************* undertakes no obligation to update such statements.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.




(C)1994-2009 M2 COMMUNICATIONS
-0-